PerrigoPRGO
PRGO
About: Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Employees: 8,379
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
489% more call options, than puts
Call options by funds: $63.2M | Put options by funds: $10.7M
23% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 47
22% more funds holding in top 10
Funds holding in top 10: 9 [Q3] → 11 (+2) [Q4]
2.42% more ownership
Funds ownership: 95.78% [Q3] → 98.2% (+2.42%) [Q4]
2% more funds holding
Funds holding: 345 [Q3] → 353 (+8) [Q4]
1% more capital invested
Capital invested by funds: $3.43B [Q3] → $3.45B (+$18.2M) [Q4]
13% less repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 136
Research analyst outlook
We haven’t received any recent analyst ratings for PRGO.
Financial journalist opinion
Negative
Seeking Alpha
1 week ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
Negative
Zacks Investment Research
1 month ago
Investing in Perrigo (PRGO)? Don't Miss Assessing Its International Revenue Trends
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Negative
Investors Business Daily
1 month ago
Do You Own 15 Stocks Morningstar Calls The Top 'Wealth Destroyers?'
The S&P 500 can generate massive wealth. But stocks can decimate portfolio values, too.
Neutral
Seeking Alpha
1 month ago
Perrigo Company plc (PRGO) 2025 Investor Day (Transcript)
Perrigo Company plc (NYSE:PRGO ) Perrigo 2025 Investor Day February 28, 2025 8:00 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Lockwood-Taylor - President and Chief Executive Officer Eduardo Bezerra - Executive Vice President and Chief Financial Officer Triona Schmelter - President of CSCA Roberto Khoury - President of CSCI Ron Janish - Head of Global Supply Chain Abbie Lennox - Chief Scientific Officer David Ball - Chief Marketing & Digital Officer Charles Atkinson - General Counsel Conference Call Participants Keith Devas - Jefferies Susan Anderson - Canaccord Korinne Wolfmeyer - Piper Sandler Chris Schott - JPMorgan Daniel Biolsi - Hedgeye Operator Welcome to Perrigo's 2025 Investor Day. [Operator Instructions] Brad Joseph Good morning, good afternoon and good evening.
Neutral
Zacks Investment Research
1 month ago
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.
Neutral
PRNewsWire
1 month ago
Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day
DUBLIN, Feb. 28, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that at its Virtual Investor Day, scheduled to begin today at 8:00 AM EST, the management team will lay out its plan to consumerize, simplify and scale its global self-care platform, with a clear path to return to stable and reliable performance. Perrigo's unique complementary businesses enables each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company's key higher margin, higher growth or 'High-Grow' brands, 2) branding and innovation capabilities that deliver brand and store brand demand generation leading to stronger customer partnerships, 3) consumer-led innovation that is scaled across brands, store brands and geographies, and 4) the Company's global supply chain scale and reach with 100-plus molecules, at 100% consumer price point coverage, serves the most consumers.
Positive
Seeking Alpha
1 month ago
31 Upcoming Dividend Increases, Including 3 Kings
This week sees 31 dividend increases, including three Dividend Kings: Genuine Parts, Commerce Bancshares, and Kimberly-Clark, showcasing impressive financial stability and growth. My investment strategy prioritizes companies with consistently rising dividends and outperforming benchmarks, aiming for long-term wealth accumulation and portfolio prosperity. I use data from the "U.S. Dividend Champions" spreadsheet and NASDAQ to identify companies with at least five years of dividend growth.
Neutral
Zacks Investment Research
1 month ago
Perrigo (PRGO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
1 month ago
Perrigo (PRGO) Q4 Earnings Beat Estimates
Perrigo (PRGO) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.86 per share a year ago.
Neutral
PRNewsWire
1 month ago
Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations
Making Significant Progress on Stabilizing, Streamlining and Strengthening Organization to Build Long-Term Sustainable, Value Accretive Growth Delivered Fiscal Year 2024 Adjusted EPS of $2.57 the Mid-Point of the Company's Communicated Guidance Range, on Reported Loss of $(1.17) Per Share Fourth Quarter 2024 Infant formula Net Sales Grew 17% Compared to the Prior Year Quarter, Due Primarily to Market Share Gains1 and Recovering Customer Inventory Levels DUBLIN , Feb. 27, 2025 /PRNewswire/ -- Fourth Quarter 2024 Highlights: Net sales of $1.14 billion declined 1.6%, as organic growth of 0.7% was more than offset by unfavorable impacts from divested businesses and exited product lines and currency translation of 2.3%. Organic2 net sales increased 0.7%, as higher net sales in the Nutrition, Skin Care and Women's Health Categories more than offset previously disclosed lost distribution of lower margin products in U.S. Store Brand of 1.2%, and lower net sales in the Pain and Sleep-Aids and Upper Respiratory categories stemming from a later start to the U.S. cough and cold season compared to the prior year.
Charts implemented using Lightweight Charts™